Canopy Growth Corporation

WEED

CA1380357048

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 16:04:57 17/07/2024 BST			5-day change	1st Jan Change
10.71 ^CAD	+6.46%		+23.58%	+57.40%

07-09	Piper Sandler Adjusts Price Target on Canopy Growth to $2 From $3, Maintains Underweight Rating	MT
07-08	Piper Sandler Maintains Canopy Growth at Underweight, Cuts Price Target to US$2.00 on Weak Sales	MT

Canopy Growth Corporation cancelled the transaction announced on January 9, 2024

January 11, 2024

On January 12, 2024, Canopy Growth Corporation terminated the subscription agreements.

Latest news about Canopy Growth Corporation

Piper Sandler Adjusts Price Target on Canopy Growth to $2 From $3, Maintains Underweight Rating	07-09	MT
Piper Sandler Maintains Canopy Growth at Underweight, Cuts Price Target to US$2.00 on Weak Sales	07-08	MT
Acreage Brief: Announcing Appointment of Rebecca Kirk as Chief Operating Officer	06-20	MT
Acreage Closes US$10-Million Private Placement of Convertible-Debenture Units	06-06	MT
Toronto Stocks Edge Higher; Transcontinental Rises on Higher 2Q Adjusted Profit	06-06	DJ
Canopy Growth Sets up $250 Million At-the-Market Equity Program; Shares Fall	06-06	MT
Canopy Growth Down 3% In US Premarket As Establishes US$250 Million At-The-Market Program To "Further Enhance the Company's Financial Position And Facilitate Growth"	06-06	MT
Canopy Growth Brief: Establishing US$250 Million At-The-Market Program To "Further Enhance the Company's Financial Position And Facilitate Growth"	06-06	MT
Canopy Growth Corporation to Seek Acquisitions	06-05	CI
Acreage Entering into US$10 Million Private Placement; Comes Amid Transaction With Canopy Growth	06-05	MT
Acreage Brief: Entering into US$10 Million Private Placement	06-05	MT
Canopy Growth Exercises Option to Acquire Class E Shares of Acreage	06-04	MT
Canopy Growth Exercises Option to Acquire Acreage Class E Shares Following on 2019 Acquisition Agreement	06-04	MT
Canopy Growth Brief: Announcing Exercise of Acreage Options "Paving the Way" for Acquisition by Canopy USA	06-04	MT
Piper Sandler Reviews Canopy Growth's Q4	05-31	MT
Transcript : Canopy Growth Corporation, Q4 2024 Earnings Call, May 30, 2024	05-30
Canopy Growth Q4 Loss Narrows as Net Revenue Rises 7%	05-30	MT
Canopy Growth Brief: Q4 FY 2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses	05-30	MT
Canopy Growth Corporation Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-30	CI
Canopy Growth Brief: Q4 Operating loss from continuing operations of $107 Million	05-30	MT
Canopy Growth Corporation Reports Earnings Results for the Full Year Ended March 31, 2024	05-30	CI
Pot stocks rise as US unveils proposal to ease restrictions on marijuana	05-16	RE
US Government Reclassifies Marijuana to Less-Restrictive Category	05-16	MT
Canopy Growth, Tilray Shares Rise After DOJ Proposes Marijuana Reclassification	05-16	DJ
Justice Department Set to Post Cannabis Reclassification Plans	05-16	MT

Chart Canopy Growth Corporation

Duration

Period

More charts

Canopy Growth Corporation is a cannabis and consumer packaged goods (CPG) company. The Company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space. Its CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a diverse range of cannabis, hemp, and cannabis products in Canada. Its Rest-of-world cannabis segment includes the production, distribution, and sale of a diverse range of cannabis and hemp products internationally. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Canopy Growth Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

10.06 CAD

Average target price

9.236 CAD

Spread / Average Target

-8.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
CANOPY GROWTH CORPORATION	+57.40%	560M
DONG-E-E-JIAO CO.,LTD.	+9.94%	4.81B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-32.21%	3.6B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.09B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	2.62B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	2.27B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	1.82B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+37.15%	1.41B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-16.01%	1.38B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.37B

Alternative Medicine